Characterization of monoclonal antibodies raised against a synthetic peptide capable of inducing a neutralizing response to human rhinovirus type 2

References

1. Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F. 1989; The three dimensional structure of foot-and-mouth disease virus at 2-9A resolution.. Nature, London 337:709–716
   [Google Scholar]
2. Appleyard G, Russell SM, Clarke BE, Speller SA, Trowbridge M, Vadolas J. 1990; Neutralization epitopes of human rhinovirus type 2.. Journal of General Virology 71:1275–1282
   [Google Scholar]
3. Bittle JL, Houghton RA, Alexander H, Shinnick TM, Sutcliffe JG, Lerner RA, Rowlands DJ, Brown F. 1982; Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence.. Nature, London 298:30–33
   [Google Scholar]
4. Booth JC, Rweyemamu MM, Pay TWF. 1978; Dose response relationships in a microneutralization test for foot-and-mouth disease viruses.. Journal of Hygiene 80:31–12
   [Google Scholar]
5. Brown AL, Francis MJ, Hastings GZ, Parry NR, Barnett PV, Rowlands DJ, Clarke BE. 1991; Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted.. Vaccine 9:595–601
   [Google Scholar]
6. Brown F. 1988; Synthetic peptides as immunogens. In Applied Virology Research vol 1 pp. 93–106Edited by Kurstak E, Murustyk RG, Murphy FA, Regenmortel MHV. New York & London: : Plenum Press;
   [Google Scholar]
7. Chow M, Yabrov R, Bittle J, Hogle J, Baltimore D. 1985; Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies.. Proceedings of the National Academy of Sciences, U.S.A. 82:910–914
   [Google Scholar]
8. Colonno RJ, Callahan PL, Long WJ. 1986; Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses.. Journal of Virology 57:7–12
   [Google Scholar]
9. Colonno RJ, Condra JH, Mizutani S, Callahan PL, Davies ME, Murcko MA. 1988; Evidence for the direct involvement of the rhinovirus canyon in receptor binding.. Proceedings of the National Academy of Sciences, U.S.A. 85:5449–5453
   [Google Scholar]
10. Colonno RJ, Callahan PL, Leippe DM, Rueckert RR, Tomassini JE. 1989; Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments.. Journal of Virology 63:36–42
    [Google Scholar]
11. DiMarchi R, Brooke G, Gale C, Cracknell V, Doel T, Mowat N. 1986; Protection of cattle against foot-and-mouth disease by a synthetic peptide.. Science 232:639–641
    [Google Scholar]
12. Emini QA, Ostapchuk P, Wimmer E. 1983; Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization.. Journal of Virology 48:547–550
    [Google Scholar]
13. Farr RS. 1958; A quantitative immunochemical measure of the primary interaction between I*BSA and antibody.. Journal of Infectious Diseases 107:239–262
    [Google Scholar]
14. Ferguson M, Evans DMA, Magrath DI, Minor PD, Almond JW, Schild GC. 1985; Induction of broadly reactive, type-specific neutralizing antibody to poliovirus type 3 by synthetic peptides.. Virology 143:505–515
    [Google Scholar]
15. Francis MJ, Hastings GZ, Sangar DV, Clark RP, Syred A, Clarke BE, Rowlands DJ, Brown F. 1987a; A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2.. Journal of General Virology 68:2687–2691
    [Google Scholar]
16. Francis MJ, Hastings GZ, Syred AD, McGinn B, Brown F, Rowlands DJ. 1987b; Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants.. Nature, London 330:168–170
    [Google Scholar]
17. Francis MJ, Hastings GZ, Campbell RO, Rowlands DJ, Brown F, Peat N. 1989; T-cell help for B-cell antibody production to rhinovirus peptides.. In Vaccines 89: Modern Approaches to New Vaccines Including Prevention of Aids pp. 437–444Edited by Lerner RA, Ginsberg HS, Chanock RM, Brown F. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
18. Greve JV, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, Kamarck ME, McClelland A. 1989; The major human rhinovirus receptor is ICAM1.. Cell 56:849–853
    [Google Scholar]
19. Hastings GZ, Speller SA, Francis MJ. 1990; Neutralizing antibodies to human rhinovirus produced in laboratory animals and humans that recognize a linear sequence from VP2.. Journal of General Virology 71:3055–3059
    [Google Scholar]
20. Hogle JM, Chow M, Filman DJ. 1985; Three dimensional structure of poliovirus at 2-9 A resolution.. Science 229:1358–1365
    [Google Scholar]
21. Houghten RA. 1985; General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proceedings of the National Academy of Sciences, U.S.A 82:5131–5135
    [Google Scholar]
22. Jackson DC, Poumbourios P, White DO. 1988; Simultaneous binding of two monoclonal antibodies separated in sequence by only three amino acid residues. Molecular Immunology 25:465–471
    [Google Scholar]
23. Jameson BA, Bonin J, Murray MG, Wimmer E, Kew O. 1985; Peptide induced neutralizing antibodies to poliovirus. Vaccines 85 pp. 191–198Edited by Lerner RA, Chanock RM, Brown F. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
24. Kim S, Smith TJ, Chapman MS, Rossmann MG, Pevear DC, Dutko FJ, Felock PJ, Diana GD, McKinlay MA. 1989; rystal structure of human rhinovirus serotype 1A (HRV1A).. Journal of Molecular Biology 210:91–111
    [Google Scholar]
25. Langedijk JP. M, Back NK. T, Durda PJ, Goudsmit J, Meloen RH. 1991; Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1.. Journal of General Virology 72:2519–2526
    [Google Scholar]
26. Luo M, Vriend G, Kamer G, Minor I, Arnold E, Rossmann MG, Boege U, Scraba DG, Duke GM, Palmenberg AC. 1987; The atomic structure of mengo virus at 3-0 A resolution.. Science 235:182–191
    [Google Scholar]
27. McCullough KC, Crowther JR, Butcher RN. 1985; Alteration in antibody reactivity with foot-and-mouth disease virus (FMDV) 146S antigen before and after binding to a solid phase or complexing with specific antibody.. Journal of Immunological Methods 82:91–100
    [Google Scholar]
28. McMaster WR, Williams AF. 1979; Identification of glycoproteins in rat thymus and purification from rat spleen.. European Journal of Immunology 9:426–433
    [Google Scholar]
29. Parry NR, Syred A, Rowlands DJ, Brown F. 1988; A high proportion of anti-peptide antibodies recognize foot-and-mouth disease virus particles.. Immunology 64:567–572
    [Google Scholar]
30. Parry NR, Ouldridge EJ, Barnett PV, Clarke BE, Francis MJ, Fox JD, Rowlands DJ, Brown F. 1989; Serological prospects for peptide vaccines against foot-and-mouth disease virus.. Journal of General Virology 70:2919–2930
    [Google Scholar]
31. Parry N, Fox G, Rowlands D, Brown F, Fry E, Acharya R, Logan D, Stuart D. 1990; Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus.. Nature, London 347:569–572
    [Google Scholar]
32. Pfaff E, Mussgay M, Bohm HO, Schulz GE, Schaller H. 1982; Antibodies against a preselected peptide recognise and neutralize foot-and-mouth disease virus.. EMBO Journal 1:869–874
    [Google Scholar]
33. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG, Rueckert RR, Sherry B, Vriend G. 1985; Structure of a human cold virus and functional relationship to other picornaviruses.. Nature, London 317:145–153
    [Google Scholar]
34. Sharon J, Givol D. 1976; Preparation of Fv fragment from the mouse myeloma XRPC-25 immunoglobulin possessing anti-dinitrophenyl activity.. Biochemistry 15:1591–1594
    [Google Scholar]
35. Skern T, Neubauer C, Frasel L, Grundler P, Sommergruber W, Zorn M, Kuechler E, Blaas D. 1987; A neutralizing epitope on human rhinovirus type 2 includes amino acid residues between 153 and 164 of virus capsid protein VP2.. Journal of General Virology 68:315–323
    [Google Scholar]
36. Staunton DR, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. 1989; A cell adhesion molecule, ICAM1, is the major surface receptor for rhino viruses.. Cell 56:849–853
    [Google Scholar]
37. Uncapher CR, DeWitt CM, Colonno RJ. 1991; The major and minor group receptor families contain all but one human rhinovirus serotype.. Virology 180:814–817
    [Google Scholar]